Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

Cell reports | Sep 26, 2013

Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not respond to the BRAF inhibitor dabrafenib. We also identified the same MEK2-Q60P mutation along with BRAF amplification in a xenograft tumor derived from a second melanoma patient resistant to the combination of dabrafenib and trametinib. Melanoma cells chronically exposed to trametinib acquired concurrent MEK2-Q60P mutation and BRAF-V600E amplification, which conferred resistance to MEK and BRAF inhibitors. The resistant cells had sustained MAPK activation and persistent phosphorylation of S6K. A triple combination of dabrafenib, trametinib, and the PI3K/mTOR inhibitor GSK2126458 led to sustained tumor growth inhibition. Hence, concurrent genetic events that sustain MAPK signaling can underlie resistance to both BRAF and MEK inhibitors, requiring novel therapeutic strategies to overcome it.

Pubmed ID: 24055054 RIS Download

Mesh terms: Cell Line, Tumor | Drug Resistance, Neoplasm | Extracellular Signal-Regulated MAP Kinases | Gene Amplification | Humans | MAP Kinase Kinase 2 | Male | Melanoma | Middle Aged | Models, Molecular | Mutation | Phosphatidylinositol 3-Kinases | Protein Kinase Inhibitors | Proto-Oncogene Proteins B-raf | Ribosomal Protein S6 Kinases

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, Id: P50 CA093372
  • Agency: NCI NIH HHS, Id: P30 CA010815
  • Agency: NCI NIH HHS, Id: P01 CA114046
  • Agency: NCI NIH HHS, Id: K01 CA175269
  • Agency: NCI NIH HHS, Id: T32 CA009615
  • Agency: NCI NIH HHS, Id: CA093372

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.